Table 3.

Inflammatory biomarker concentrations at baseline and 12 months in controls and exercisers stratified by adherence level

Baseline12 Months
Geometric mean (95% CI)Geometric mean (95% CI)Ratio 12 months/baseline (95% CI)cPercent changedPePtrendf
CRPb (mg/L)
 Controlsa1.3 (1.1–1.5)1.3 (1.1–1.5)0.99 (0.89–1.11)–0.6Ref0.021
 <150 min/wka1.3 (1.0–1.7)1.2 (0.9–1.5)0.92 (0.74–1.14)–8.20.489
 150–225 min/wka1.5 (1.2–2.0)1.3 (1.0–1.6)0.82 (0.68–1.00)–17.70.146
 >225 min/wka1.2 (0.9–1.6)1.1 (0.7–1.3)0.82 (0.72–0.94)–17.80.036
IL-6 (pg/mL)
 Controls1.6 (1.4—1.7)1.6 (1.4–1.7)1.01 (0.93–1.10)1.1Ref0.633
 <150 min/wk1.4 (1.1–1.7)1.6 (1.2–2.0)1.11 (0.91–1.36)11.40.479
 150–225 min/wk1.5 (1.4–1.7)1.5 (1.3–1.7)0.97 (0.86–1.11)–2.60.572
 >225 min/wk1.4 (1.2–1.7)1.5 (1.2–1.8)1.02 (0.85–.21)1.50.813
TNF-α (pg/mL)
 Controls1.4 (1.4–1.5)1.4 (1.3–1.4)0.94 (0.91–0.97)–6.3Ref0.910
 <150 min/wk1.6 (1.4–1.8)1.4 (1.2–1.5)0.87 (0.78–0.97)–13.00.142
 150–225 min/wk1.5 (1.4–1.7)1.5 (1.3–1.6)0.94 (0.88–1.01)–5.70.535
 >225 min/wk1.5 (1.4–1.6)1.3 (1.2–1.5)0.91 (0.86–0.97)–8.60.487
  • an = 156, 40, 67, and 47 for controls and 3 exercise adherence levels of 150 or less, 150 to 225, more than 225 min/wk, respectively.

  • bTop 1% of CRP measures were excluded from analyses; resulting sample sizes were n = 153, 38, 65, and 46, respectively—in total 8 less than before.

  • cRatio of geometric means at 12 months to geometric means at baseline.

  • dPercentage biomarker change at 12 months from baseline for that level or group.

  • eP values for biomarker change at 12 months from baseline between controls and that level of exercise adherence, adjusted for the baseline value.

  • fTrend test for biomarker change at 12 months from baseline across controls and 3 adherence groups, adjusted for the baseline value.